Loading the security overview…
Where the tokens are
Standardised from the company’s filings, newest period first, labelled with the company’s own fiscal calendar. A line the company does not report is left off rather than shown as zero; margins and free cash flow are worked out here, and only where every input is present.
| Line item | Q2 FY262026-06-27 | Q1 FY262026-03-28 | Q4 FY252025-12-31 |
|---|---|---|---|
| Revenue | $7.69B | $7.35B | — |
| Cost of revenue | $5.47B | $5.51B | $0 |
| Gross profit | $2.22B | $1.84B | — |
| Gross margin | 28.8% | 25.0% | — |
| Selling, general and administrative | $1.30B | $1.23B | — |
| Operating expenses | $1.82B | $1.42B | — |
| Operating income | $395.00M | $422.00M | — |
| Operating margin | 5.1% | 5.7% | — |
| EBITDA | $651.00M | $676.00M | $0 |
| Interest expense | −$119.00M | −$136.00M | — |
| Income before taxes | $235.00M | $291.00M | — |
| Income taxes | $96.00M | $52.00M | — |
| Net income | $139.00M | $239.00M | — |
| Net margin | 1.8% | 3.3% | — |
| EPS, basic | $0.07 | $0.16 | — |
| EPS, diluted | $0.07 | $0.16 | — |
| Diluted shares | 860.89M | 824.84M | 809.69M |
Figures describe Medline shares, not any token. As of Aug 5, 2026, from Massive's standardised financials. The company reports these figures; a token's issuer holds the shares and reports nothing of its own here.